
- Psychiatric Times Vol 36, Issue 2
- Volume 36
- Issue 2
Immunotherapy as Personalized Medicine for Schizophrenia?
Two compelling case reports provide additional evidence for potential mechanistic associations between the immune system and schizophrenia.
The investigation of immune system abnormalities in schizophrenia, though ongoing for decades, has received significant renewed interest, stimulated in part by our increased understanding of brain-immune interactions that occur in other chronic medical disorders. Two compelling case reports provide additional evidence for potential mechanistic associations between the immune system and schizophrenia.
Immune dysfunction in schizophrenia
Conversely,
Indeed, schizophrenia is associated with immune system abnormalities throughout the lifespan (see
Patients with schizophrenia have immune abnormalities in the blood, cerebrospinal fluid, and CNS, including immune cell numbers, inflammatory markers, and antibody titers.3,5 There is also
Although there are a number of well-replicated findings in this area, the effect sizes are small to moderate for many associations, and there are also negative studies. There are many potential explanations for these discrepancies, including small sample sizes, stage of illness, medication status, comorbid conditions, and potential confounding or moderating factors such as obesity and smoking. Another important potential explanation for these heterogeneous findings is that immune system dysfunction occurs in only a subset of patients with schizophrenia. This may reflect an inherent limitation of our phenomenologically based nosology.
Adjunctive anti-inflammatory agents in schizophrenia
Importantly, findings indicate that treatment with NSAIDs as adjuncts to antipsychotics may be associated with significant improvement in psychopathology in schizophrenia.7-9 Additionally, baseline blood levels of cytokines-key signaling molecules that regulate inflammation-may predict treatment response to these agents.
In an analysis of 26 double-blind trials of various agents with anti-inflammatory properties,
Results from
The small-to-moderate effect sizes for the efficacy of adjunctive NSAIDs most likely reflects that immune dysfunction occurs in only a subset of patients with schizophrenia. Two important limitations of these studies are that: NSAIDs have relevant off-target (ie, non-immune) effects and evidence of immune dysfunction (eg, the presence of increased inflammation in the peripheral blood, as measured by C-reactive protein [CRP]) was not an inclusion criterion, which may have decreased the signal-to-noise ratio in these trials.
Immunotherapy
In contrast with NSAIDs, monoclonal antibodies, also termed biologic agents or “biologics,” target specific inflammatory cytokines or cytokine receptors. These agents are used in the treatment of certain chronic diseases, including hepatitis C, malignant melanoma, and autoimmune disorders such as rheumatoid arthritis and multiple sclerosis. Intriguingly,
There are several major potential advantages of monoclonal antibody immunotherapy over NSAIDs or other anti-inflammatory agents as adjunctive treatments for schizophrenia (
Compared with NSAIDs, monoclonal antibodies have more potent anti-inflammatory properties. Indeed, NSAIDs have minimal efficacy in conditions with significant inflammation, such as autoimmune disorders. The small-to-moderate effect sizes for improvements in psychopathology with adjunctive NSAIDs may also suggest that more potent anti-inflammatory agents are needed for more robust effects. Presently, most monoclonal antibodies are administered by intravenous (IV) infusion (although some agents can be given subcutaneously or orally), typically once a month. From a research perspective, this is advantageous in terms of obviating issues of medication adherence that may confound findings.
Early studies of adjunctive monoclonal antibody immunotherapy in schizophrenia
In parallel with the evolution of mono- clonal antibody immunotherapy in other chronic disorders, there are nascent studies of these agents in schizophrenia.
In an 8-week
A
1. Although the authors found that baseline CRP did not predict treatment outcome, evidence of inflammation was not an inclusion criterion. Therefore, the number of subjects with evidence of inflammation who received tocilizumab was small, and the study may have been underpowered to detect such an association.
2. Subjects in this trial were clinically stable at study entry. Previous meta-analyses suggest that response to adjunctive NSAIDs may be more robust in acutely ill patients.
3. Baseline assessments were completed within 2 weeks of the first infusion of study drug. It is possible, therefore, that some clinical improvement in this trial was not captured due to this modest delay in assessment.
Considerations in schizophrenia immunotherapy
These early studies highlight some of the challenges and complexities of trials of monoclonal antibody immunotherapy in schizophrenia.
Monoclonal antibodies that target the cytokines IL-1, IL-6, IL-12/23, IL-17, and TNF-α, the cell adhesion molecule α4-integrin, and B-cell activation are approved for use in autoimmune and inflammatory disorders.16
A number of trials of adjunctive treatment with these agents in schizophrenia are planned or ongoing. These trials will largely focus on patients with evidence of baseline inflammation (eg, elevated blood CRP), as this approach may increase both the likelihood of response as well as the study’s signal-to-noise ratio. Studies will investigate canakinumab (anti-IL-1β mAb;
Several other important considerations in the design and implementation of monoclonal antibody immunotherapy clinical trials include the timing and duration of therapy during the course of schizophrenia. In a
Illness phase and duration of treatment are also important considerations. For example, is it pragmatic to expect improved psychopathology in patients with chronic illness, or should immunotherapy be considered in earlier phases of illness? The majority of previous trials of adjunctive NSAIDs were of shorter (<12 weeks) duration and in acutely ill patients. Thus, it is not clear whether anti-inflammatory treatments help patients reach a new, lower baseline level of symptoms, or if they accelerate the speed of response to psychotropic medications during periods of acute illness.
The risk of serious adverse effects due to profound immunosuppression, including demyelinating disorders, ulcers, and malignancy with long-term monoclonal antibody immunotherapy, must also be considered (
The high cost of adjunctive monoclonal antibody immunotherapy (potentially >$1000 per dose) is another important factor that may limit use. Furthermore, the IV route of administration poses a myriad of logistical issues for patients and clinicians in terms of time, facilities, and equipment to perform infusions, as well as monitoring for patient safety (eg, risk of anaphylaxis during and after the infusion).
Conclusions
The available data do not support the widespread clinical utility of measuring inflammatory markers such as blood CRP levels in patients with schizophrenia and prescribing adjunctive NSAIDs or monoclonal antibody immunotherapy for those with evidence of abnormality. Nevertheless, there is a compelling rationale for well-designed, carefully conducted trials of monoclonal immunotherapy in schizophrenia, which will permit direct testing of the hypothesis that immune dysfunction, including inflammation, plays a causal role in psychopathology. It will be interesting to observe whether such highly selective strategies will pay off and whether the therapeutics of schizophrenia will broaden to encompass immune-based approaches. These studies, regardless of outcome, will provide valuable insights into the effects of the immune system on brain and behavior, and represent an important potential step towards more personalized medicine for patients with schizophrenia.
Disclosures:
Dr Miller is Associate Professor of Psychiatry, Department of Psychiatry and Health Behavior, Augusta University, Augusta, Georgia.
Dr Miller reports that he receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute.
References:
1. Sommer I, van Bekkum D, Klein H, et al.
2. Miyaoka T, Wake R, Hashioka S, et al.
3. Goldsmith DR, Rapaport MH, Miller BJ.
4. Benros ME, Pedersen MG, Rasmussen H, et al.
5. Kirkpatrick B, Miller BJ.
6. Eaton W, Byrne M, Ewald H, et al.
7. Nitta M, Kishimoto T, Müller N, et al.
8. Muller N Ulmschneider M, Scheppach C, et al.
9. Laan W, Grobbee DE, Selten JP, et al.
10. Sommer I, van Westrhenen R, Begemann M, et al.
11. Xiang YQ, Zheng W, Wang SB, et al.
12. Miller BJ, Buckley PF.
13. Grüber L, Bunse T, Weidinger E, et al.
14. Miller BJ, Dias JK, Lemos HP, et al.
15. Girgis RR, Ciarleglio A, Choo T et al.
16. Miller AH, Haroon E, Felger JC.
Articles in this issue
over 6 years ago
Introduction: Convergence of Thought?over 6 years ago
Project Untangled: A Journey of Hope and Healingover 6 years ago
Anxiety Disorders in Children and Adolescents: New Findingsover 6 years ago
Coaching Families to Address Addictionover 6 years ago
Embracing Changesover 6 years ago
US Life Expectancy: The Mental Health Perspectiveover 6 years ago
The Changing Face of Psychiatry in the Age of Climate ChangeNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.